Welcome to our dedicated page for Nanobiotix S.A. news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix S.A. stock.
Nanobiotix S.A. (NBTX) news covers developments at a late-stage clinical biotechnology company that focuses on physics-based therapeutic approaches and nanotechnology platforms. As a dual-listed issuer on Euronext Paris and the Nasdaq Global Select Market, Nanobiotix regularly publishes updates that are relevant to investors following oncology-focused biotechnology and pharmaceutical preparation manufacturing.
Company news frequently highlights progress in the JNJ-1900 (NBTXR3) clinical program, including updates on the global Phase 3 NANORAY-312 study in locally advanced head and neck squamous cell cancers and Phase 1 and Phase 2 studies sponsored by Nanobiotix or The University of Texas MD Anderson Cancer Center. Releases may also describe regulatory designations, collaboration milestones with Janssen Pharmaceutica NV, and the transfer of sponsorship and operational control of key trials.
Another recurring theme in Nanobiotix news is the Curadigm Nanoprimer platform. The company reports on new patent applications, preclinical in vivo data, and Chemistry, Manufacturing, and Controls (CMC) activities, as well as material transfer agreements with biotechnology and pharmaceutical partners evaluating Nanoprimer combinations with intravenously administered therapeutics.
Investors can also find announcements related to capital markets activity, such as royalty-based financing agreements with HealthCare Royalty (HCRx), inclusion in the CAC Mid 60 and SBF 120 indices on Euronext Paris, and periodic disclosures on shares outstanding and voting rights under French regulations. In addition, Nanobiotix issues notices about participation in investor and healthcare conferences, where management presents the company’s strategy and clinical pipeline.
By following NBTX news, readers can track clinical, financial, and strategic updates that shape the company’s development trajectory and its work in oncology, drug bioavailability and biodistribution, and central nervous system disorder applications.
Nanobiotix (NASDAQ: NBTX), a late-clinical stage biotechnology company focused on nanoparticle-based cancer treatments, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's Chief Financial & Business Officer, Bart van Rhijn, will participate in a fireside chat on June 5, 2025, at 3:45 PM EDT in New York. The presentation will be accessible via webcast on the company's investor relations website, with a replay available after the event.
Nanobiotix (NBTX) reported key operational and financial updates for Q1 2025. The company achieved significant milestones in its JNJ-1900 (NBTXR3) development programs, including the dosing of the first patient in the CONVERGE Phase 2 study for stage 3 unresectable non-small cell lung cancer. Clinical data presentations at major conferences demonstrated promising results in lung cancer re-irradiation and pancreatic cancer studies.
The company strengthened its financial position through an amendment to the global licensing agreement for JNJ-1900, which extended its cash runway into mid-2026 and reduced operational cash burn. As of March 31, 2025, Nanobiotix reported €39.8 million in cash and cash equivalents. The agreement modification removed most funding obligations for NANORAY-312 while maintaining potential milestone and royalty payments.
Nanobiotix (NBTX) has reported its latest voting rights and share capital status as of April 30, 2025. The company disclosed having 47,426,851 shares outstanding, with 49,535,883 theoretical voting rights and 49,513,765 exercisable voting rights. This regular monthly disclosure is required by French regulatory authorities for companies listed on Euronext Paris.
Nanobiotix (NASDAQ: NBTX), a late-clinical stage biotechnology company focused on nanoparticle-based cancer treatments, announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ. The company's Chief Financial & Business Officer, Bart van Rhijn, will participate in a fireside chat on Tuesday, May 20, 2025, at 5:00 pm EDT in New York. The presentation will be webcast live and available for replay on the company's investor relations website.
Nanobiotix (NBTX) announced full results from a completed Phase 1 study of JNJ-1900 (NBTXR3) in pancreatic cancer patients. The study, conducted at MD Anderson Cancer Center, showed promising outcomes in patients with locally advanced or borderline resectable pancreatic cancer (n=22). Key findings include:
- Median Overall Survival of 23 months from diagnosis [compared to 19.2 months historical data] - Median Local Progression-Free Survival of 13.3 months from radiation completion - CA19-9 normalization in 59% of patients (vs 17% historical data) - Two LAPC patients achieved R0 surgical resection - Favorable safety profile and injection feasibility
The study has expanded with a new cohort combining JNJ-1900 with standard-of-care concurrent chemoradiation after induction chemotherapy, with the first patient already injected.
Nanobiotix has announced the upcoming presentation of complete results from their Phase 1 study of JNJ-1900 (NBTXR3) in pancreatic cancer patients. The presentation will take place at ESTRO 2025 on May 4th at 11:00 AM EDT, delivered by Principal Investigator Dr. Eugene Koay.
The study focused on patients with locally advanced or borderline resectable pancreatic cancer, conducted at The University of Texas MD Anderson Cancer Center. Following the presentation, Nanobiotix will host a conference call on May 5th at 8:00 AM EDT, featuring CEO Laurent Levy to discuss the findings.
The company, listed on both Euronext (NANO) and NASDAQ (NBTX), is advancing their nanoparticle-based therapeutic approach to expand cancer treatment options. Participants can join the discussion through either a webcast or audio-only option, with the opportunity to submit questions in advance to investors@nanobiotix.com.
Nanobiotix (NBTX) has released its latest voting rights and share capital statement as of March 31, 2025. The company reported 47,426,851 shares outstanding, with 49,193,374 theoretical voting rights and 49,171,256 exercisable voting rights. This disclosure complies with French regulatory requirements, including the French Commercial Code and Financial Markets Authority regulations.
Nanobiotix (NBTX) has reported its full year 2024 financial results and business updates. The company's lead product JNJ-1900 (NBTXR3) continues development in head and neck cancer and lung cancer programs. Key highlights include:
- Cash position of €49.7 million as of December 31, 2024, with runway extended into mid-2026
- Negative revenues of €7.2 million in 2024 (compared to €36.2 million in 2023)
- Net loss increased 72% to €68.1 million (€1.44 per share)
- R&D expenses rose 5% to €40.5 million
- SG&A expenses decreased 7% to €20.5 million
Notable operational progress includes first patient dosing in the Phase 2 CONVERGE study for lung cancer, completion of pancreatic cancer Phase 1 study, and launch of Curadigm platform. The company amended its global licensing agreement with Johnson & Johnson, reducing funding obligations while maintaining milestone payment potential.
Nanobiotix (NASDAQ: NBTX), a late-clinical stage biotechnology company focused on nanoparticle-based cancer treatments, will release its Q4 and full-year 2024 financial results on April 2, 2025, after U.S. market close.
The company will host a conference call and webcast on April 3, 2025, at 8:00 AM EDT / 2:00 PM CEST. CEO Laurent Levy and CFO Bart van Rhijn will present the year-end results and provide a business update for Q4 and full year 2024, followed by a Q&A session.
Nanobiotix (NBTX) has released initial data from a completed Phase 1 dose escalation study evaluating NBTXR3 (JNJ-1900) as a second-line or later therapy for locally advanced non-small cell lung cancer (NSCLC) patients eligible for re-irradiation.
The study, conducted at MD Anderson Cancer Center, demonstrated favorable safety outcomes with no dose-limiting toxicities or Grade 3+ serious adverse events related to NBTXR3. The recommended phase 2 dose was established at 33% of gross tumor volume.
Preliminary survival data from 12 patients showed promising results with:
- 12-month local progression-free survival (LPFS) of 64% (median 18.6 months)
- 12-month overall survival (OS) of 83% (median 30.2 months)
The expansion phase is currently ongoing with 5 out of 12 patients injected to date.
FAQ
What is the current stock price of Nanobiotix S.A. (NBTX)?
What is the market cap of Nanobiotix S.A. (NBTX)?
